Rasit Dinc

Prof. Dr. Rasit Dinc

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2022 in The Korean Journal of Parasitology
Verified
Journal Article
Open access
PDF file
RDRasit Dinc
Rasit Dinc
Leishmaniasis is a serious parasitic disease caused by Leishmania spp. transmitted through sandfly bites. This disease is a major public health concern worldwide. It can occur in 3 different clinical forms: cutaneous, mucocutaneous, and visceral Leishmaniasis (CL, MCL, and VL, respectively), caused by different Leishmania spp. Currently, licensed vaccines are unavailable for the treatment of human Leishmaniasis. The treatment and prevention of this disease rely mainly on chemotherapeutics, which are highly toxic and have an increasing resistance problem. The development of a safe, effective, and affordable vaccine for all forms of vector-borne disease is urgently needed to block transmission of the parasite between the host and vector. Immunological mechanisms in the pathogenesis of Leishmaniasis are complex. IL-12-driven Th1-type immune response plays a crucial role in host protection. The essential purpose of vaccination is to establish a protective immune response. To date, numerous vaccine studies have been conducted using live/attenuated/killed parasites, fractionated parasites, subunits, recombinant or DNA technology, delivery systems, and chimeric peptides. Most of these studies were limited to animals. In addition, standardization has not been achieved in these studies due to the differences in the virulence dynamics of the Leishmania spp. and the feasibility of the adjuvants. More studies are needed to develop a safe and effective vaccine, which is the most promising approach against Leishmania infection.

1 July 2025 in Health Informatics Journal
Verified
Journal Article
Open access
NANurittin Ardic
Nurittin Ardic
RDRasit Dinc
Rasit Dinc
Multimodal artificial intelligence (MMAI) integrates and interprets diverse data types, such as images, text, video, and audio, and offers new opportunities for clinical decision support systems (CDSSs). Traditional CDSSs rely on unimodal data, which limits their predictive accuracy and coverage. The incorporation of MMAI holds promise for more accurate diagnosis, treatment optimization, and personalized patients care by synthesizing heterogeneous data sources. This narrative review explores the growing role of MMAI in improving diagnostic sensitivity, personalizing treatment, and improving healthcare delivery through the integration of heterogeneous data sources. It examines the evolution of MMAI technologies, such as large language models, large vision models, vision-language models, and large multimodal models, and their practical applications in clinical settings. The review also addresses key ethical, technical, and infrastructure challenges, such as data quality, model interpretability, bias, and system interoperability. Finally, it provides strategic recommendations for clinicians, researchers, and policy makers to promote responsible adoption of MMAI in healthcare. While recent developments show significant promise, addressing current limitations is essential to fully realize the transformative potential of MMAI in modern medicine.

25 August 2025 in British Journal of Hospital Medicine
Verified
Journal Article
Closed access
NANurittin Ardic
Nurittin Ardic
RDRasit Dinc
Rasit Dinc
The integration of artificial intelligence (AI) in healthcare offers the potential to play a critical role in reshaping clinical practice. However, it also brings regulatory, ethical, implementation, social, and technical challenges that healthcare systems must overcome. It is necessary for the responsible parties in AI applications to be well defined by the regulations. To create standards that encourage innovation and address ethical and security concerns, collaboration between policymakers, AI developers and healthcare providers has a vital role. In this review, it was presented an overview of the current regulatory landscape for AI in healthcare, focusing primarily on frameworks in the European Union (EU), the United States (USA), and the United Kingdom (UK), which are leading countries in this regard. The review also emphasized the challenges that need to be addressed.

1 January 2023 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
RDRasit Dinc
Rasit Dinc
Dinc R. Transl Clin Pharmacol. 2023 Nov;31:e18. https://doi.org/10.12793/tcp.2023.31.e18

5 February 2026 in Cells
Verified
Journal Article
Open access
PDF file
RDRasit Dinc
Rasit Dinc
NANurittin Ardic
Nurittin Ardic
Exosomes and other extracellular vesicles (EVs) carry microRNAs, proteins, and lipids that reflect cardiovascular pathophysiology and can enable minimally invasive biomarker discovery. However, EV datasets are highly dimensional and heterogeneous, strongly influenced by pre-analytic variables and non-standardized isolation/characterization workflows, limiting reproducibility across studies. Artificial intelligence (AI), including machine learning (ML), deep learning (DL), and network-based approaches, can support EV biomarker development by integrating multi-omics profiles with clinical metadata. These approaches enable feature selection, disease subtyping, and interpretable model development. Among the AI approaches evaluated, ensemble methods (Random Forest, gradient boosting) demonstrate the most consistent performance for EV biomarker classification (AUC 0.80–0.92), while graph neural networks (GNNs) are particularly promising for path integration but require larger validation cohorts. Evolutionary neural networks applied to EV morphological features yield comparable discrimination but face interpretability challenges for clinical use. Current studies report promising discrimination performance for selected EV-derived panels in acute myocardial infarction and heart failure. However, most evidence remains exploratory, based on small cohorts (n < 50) and limited external validation. For clinical implementation, EV biomarkers need direct comparison against established standards (high-sensitivity troponin and natriuretic peptides), supported by locked-in assay plans, and validation in multicenter cohorts using MISEV-aligned protocols and transparent AI reporting practices. Through a comprehensive, integrative, and comparative analysis of AI methodologies for EV biomarker discovery, together with explicit criteria for reproducibility and translational readiness, this review establishes a practical framework to advance exosomal diagnostics from exploratory research toward clinical implementation.

30 September 2025 in Journal of Preventive Medicine and Public Health
Verified
Journal Article
Open access
PDF file
RDRasit Dinc
Rasit Dinc
NANurittin Ardic
Nurittin Ardic
Artificial intelligence (AI)-enabled technologies have the potential to significantly increase diagnostic accuracy, optimize treatment strategies, and improve patient outcomes. They are revolutionizing the field of preventive and personalized medicine by providing data-driven insights. AI is capable of analyzing large and complex datasets such as genomic, environmental, and lifestyle information much faster and more conveniently than traditional methods. Advanced algorithmic architectures in AI can predict disease risks, identify biomarkers, and tailor interventions to individual needs. The enabling role of AI in real-time monitoring, predictive analysis, and drug discovery demonstrates its transformative potential in healthcare. The role of AI in multi-omics integration, wearable technologies, and precision therapies promises to redefine global healthcare paradigms, making personalized medicine more accessible and effective. However, ethical concerns that need to be addressed to ensure fair and transparent implementation include data privacy, algorithmic bias, and regulatory gaps. This article examines the integration of AI technologies with personalized healthcare. The study also highlights the need for interdisciplinary collaboration to maximize the benefits of AI in preventive and personalized healthcare and overcome barriers.